Lipocalin 2 in the pathogenesis of fatty liver disease and nonalcoholic steatohepatitis

Q Medicine

Clinical Lipidology Pub Date : 2015-02-01 DOI:10.2217/clp.14.65

A. Asimakopoulou, R. Weiskirchen

引用次数: 12

Abstract

Abstract The lipocalins were originally classified as a widespread group of transport proteins for small hydrophobic molecules. Although they only share a limited sequence homology their 3D fold is conserved. This group of proteins has been implicated in a multitude of biological processes that most often become visible during disease formation. Lipocalin 2 (LCN2) serves as a siderocalin and protects against bacterial infections. In the liver, LCN2 expression is upregulated during inflammation and in response to cellular stress evolving protective effects during acute and chronic injury. LCN2 was shown to act as an adipokine in the pathogenesis of nonalcoholic fatty liver disease and in control of brown adipose tissue activation. In a nutritional model of nonalcoholic steatohepatitis, LCN2 was identified as a key factor that controls the expression of the perlipin 5 regulating cellular lipid droplet formation. We here summarize experimental and clinical findings linking LCN2 to fatty liver disease.

查看原文本刊更多论文

脂钙蛋白2在脂肪肝和非酒精性脂肪性肝炎发病机制中的作用

脂钙蛋白最初被归类为广泛存在的一组小疏水分子运输蛋白。虽然它们只有有限的序列同源性，但它们的三维折叠是保守的。这组蛋白质与许多在疾病形成过程中最常见的生物过程有关。脂钙蛋白2 (LCN2)作为一种铁钙蛋白，可以防止细菌感染。在肝脏中，LCN2的表达在炎症和细胞应激反应中上调，从而在急性和慢性损伤中发挥保护作用。LCN2在非酒精性脂肪性肝病的发病机制和控制棕色脂肪组织激活中发挥脂肪因子的作用。在非酒精性脂肪性肝炎的营养模型中，LCN2被确定为控制调节细胞脂滴形成的高脂素5表达的关键因子。我们在此总结LCN2与脂肪肝疾病相关的实验和临床发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.